Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

• Status: Terminated
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly. This study is being done to see how colorectal cancer responds to treatment with the combination of bevacizumab and chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NSABP Foundation Inc
• Collaborators: Genentech, Inc.; Hoffmann-La Roche; International Drug Development Institute
• Treatments: Bevacizumab; Camptothecin; Capecitabine; Irinotecan; Oxaliplatin

Criteria

Inclusion Criteria:

• Pathological diagnosis of colon or rectal cancer from either the colon or rectum or a metastatic site (beyond the colon or rectum)

• Evidence of adequate organ function (such as liver, kidneys, etc.)

Exclusion Criteria:

• Diagnosis of anal cancer

• Patients who are candidates for surgery

• Patients who have received previous treatments

• Pregnant or lactating women

• History of chronic disease(s) or other serious medical conditions